GLP-1 medications can create metabolic conditions that may support fungal overgrowth, including elevated urinary glucose and immune system shifts. Understanding baseline risk factors and monitoring strategies helps providers optimize treatment safely.

Semaglutide side effects like nausea and GI symptoms affect many patients, but strategic dose titration, dietary adjustments, and personalized monitoring can significantly improve tolerability. Understanding your individual risk factors supports informed conversations with providers about prevent...

Semaglutide side effects often emerge within days to weeks of starting treatment, with timing influenced by dose escalation, individual metabolism, and genetic factors affecting GLP-1 receptor sensitivity. Understanding your genetic predisposition may help inform realistic expectations with your ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. This means it mimics a hormone naturally produced in your gut called GLP-1, which plays a role in controlling appetite, insulin secretion, and blood sugar regulation.

Semaglutide demonstrates clinically meaningful weight loss in most patients, with studies showing 5-22% body weight reduction depending on dose and duration. However, response variability is substantial, and emerging evidence suggests genetic predispositions in GLP-1 pathways may help explain why...

The honest 2026 trade-off on GLP-1 medications: substantial weight loss and cardiometabolic benefits balanced against GI side effects, cost, lean-mass loss risk, and long-term maintenance. Compares branded vs compounded options and where PlexusDx Weight Management Protocols fit at $129–$509/mo across six protocols.

An honest read on the cons of GLP-1 therapy — GI side effects, the boxed warning, cost, weight regain on cessation, and body composition — plus where PlexusDx Weight Management Protocols ($129–$325/mo, all 50 states, no membership) fit when insurance friction is itself one of the cons.

Ozempic nausea is real, dose-related, and highly responsive to specific food and timing choices. This guide covers what to eat right now (bland, low-fat, small portions), what to drink (room-temp water, ginger tea, broth), what to avoid (fatty/fried/spicy/carbonated), and when to call a clinician. Plus how PlexusDx Semaglutide Injection ($179–$229/mo), the Microdose GLP-1 Protocol ($129/mo flat), and the Optimal Diet & Weight Loss Genetic Test ($298) fit into a tolerable, sustainable GLP-1 plan.

FDA labels list hair loss in 3% of Wegovy and 4–5% of Zepbound users, but the real trigger is rapid weight loss producing telogen effluvium — a reversible 6–12 month shedding pattern. This guide covers the FDA evidence, the timeline you can plan around, why women report it more often, the genetic variants behind GLP-1 response, and how a slower-titration PlexusDx protocol plus the Precision Peptide Genetic Test reduces risk before week one.

Practical, food-by-food playbook for managing Zepbound (tirzepatide) nausea: what to eat in the first 24 hours after your shot, what to drink, what to avoid, when to call your doctor, and how genetic variants in GLP1R, GIPR, and gastric-emptying genes explain why some patients are far more sensitive than others. Includes how PlexusDx Tirzepatide Injection ($229-$309/mo) and Tirzepatide Oral ($229-$509/mo) compounded protocols, paired with the Precision Peptide Genetic Test, let your clinician anchor titration to your biology.

Mounjaro side effects from the FDA-approved label — common GI reactions (nausea, vomiting, diarrhea, constipation, abdominal pain), less common serious reactions (pancreatitis, gallbladder disease, acute kidney injury), and the boxed warning for thyroid C-cell tumors with MTC and MEN 2 contraindications. Plus how compounded tirzepatide protocol oversight from PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo) compares, and where the Precision Peptide Genetic Test fits as a $99 add-on for GLP1R, GIPR, FTO, MC4R, and TCF7L2 baseline.

Constipation is one of the most common GLP-1 side effects — here's the food, fluid, movement, and dose-adjustment playbook that actually works, plus where the PlexusDx Microdose GLP-1 Protocol and Precision Peptide Genetic Test fit in.

What's common, what's serious, and how to manage GLP-1 side effects from FDA-labeled known information — including the boxed warning that applies to both semaglutide and tirzepatide, when to call your provider, and how PlexusDx structures titration and the optional Precision Peptide Genetic Test.

Zepbound (tirzepatide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Victoza (liraglutide, Novo Nordisk) is a once-daily GLP-1 receptor agonist FDA-approved in 2010. This article covers common GI side effects, serious warnings including the boxed warning for thyroid C-cell tumor risk, long-term post-marketing signals, what typically improves, and when to seek medical care — all as of April 2026.

Semaglutide (semaglutide, marketed under multiple brand names (Ozempic, Wegovy, Rybelsus); also available through licensed compounding pharmacy pathways) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Retatrutide (retatrutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Trulicity (dulaglutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Rybelsus (oral semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Mounjaro (tirzepatide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Ozempic (semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Wegovy (semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.